Randomized trial of entecavir plus interferon versus lamivudine plus interferon in chronic hepatitis B in children.

jjal Poddar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Children with either immune tolerant or immune reactive HBV will be included:Immune tolerant group: Children: 2-18 years of age of either sex with chronic HBV (HBsAg+ve for more than 24 weeks, HBeAg+ve, anti HBe-ve, DNA > 108IU/ml with normal or near normal ALT (within 2 times ULN) and liver histology shows normal or minimal changes.
•Immune clearance or immune-reactive group: Children: 2-18 years of age of either sex with chronic HBV (HBsAg+ve for more than 24 weeks, HBeAg+ve, anti HBe-ve, DNA > 20,000 IU/ml but < 108 IU/ml with raised ALT ( > 2 times ULN) and liver histology shows necro-inflammatory activities.

•Children less than 2 years of age, co-infection with HCV and HIV, advanced liver disease (decompensated cirrhosis), associated autoimmune diseases, neuropsychiatric illness, low platelet counts ( < 1, 00, 000), low total leucocyte count ( <3, 000), age <24 months, previous history of interferon or antiviral therapy.

发起方

jjal Poddar